Functional significance of RARb2 as a putative tumor suppressor gene has been studied in breast cancer and other tumors. The long 5 0 -untranslated region (5 0 -UTR) of its transcript with multiple open-reading frames (uORFs) is considered as a regulatory unit for translation. Here, for the first time we identified RARb2 transcript variants with short 5 0 -UTRs in both normal and malignant breast epithelial cells. The 5 0 -RACE analysis of RARb2 mRNA in these cells demonstrated the existence of short RARb2 transcript variants that are identical to the sequence of known RARb2, but lack all the uORFs present in the fulllength 5 0 -UTR. By RT-PCR analysis, we found that the expression of both transcripts with short and full-length 5 0 -UTR is mediated by retinoic acid, while cellular sensitivity is preferentially correlated to upregulation of short RARb2 transcript variants in response to retinoic acid. The transfection and in vitro translation assay indicated that the short 5 0 -UTR has no inhibitory effects on translation, while the presence of full-length 5 0 -UTR inhibited translation by 60%. In addition, no promoter activity was detectable in RARb2 full-length 5 0 -UTR region. Our data suggest that the RARb2 transcript variants with short 5 0 -UTR may serve as major transcripts for RARb2 protein translation as well as potential targets for retinoids in breast cancer prevention and therapy studies. Oncogene (2005) The clinical significance of retinoids in prevention and treatment has been well established for the cancers of many target organs including breast (Tallman and Wiernik, 1992; Lippman et al., 1995; Lotan, 1996) . The biological effects of retinoids are mainly mediated by retinoic acid receptors (RARs and RXRs), each consisting of three receptor subtypes (a, b, g) (Giguere, 1994; Chambon, 1996) . As the primary effectors of retinoid signaling, the RARs and RXRs themselves appear to be targets for disruption in tumorigenesis (Chen et al., 2002) . For example, the RARb expression is lost during carcinogenesis, suggesting that it may play a role in tumor suppression (Deng et al., 1996; Widschwendter et al., 1997; Xu et al., 1997) . So far the identified human RARb2 transcript has a long 5 0 -untranslated region (5 0 -UTR, 468 nucleotides) that can form stable secondary structures and contains five small open-reading frames (uORFs) preceding the major ORF (de Zelent et al., 1991) . The uORFs present in the 5 0 -UTR usually inhibit translation from downstream (Gray and Wickens, 1998) and therefore they may greatly decrease the translation efficiency of RARb2. However, it has also been reported that the uORFs of RARb2 mRNA plays a role in the control of tissue-specific and developmentally regulated gene expression (Zimmer et al., 1994) .
We have been interested in RAR/RXR alterations in the process of breast tumor progression using MCF10 series of breast epithelial cell lines as a model system (Santner et al., 2001; Peng et al., 2004b) . During the characterization of RARb expression in these cell lines, we found that RARb2 transcript was not detectable by PCR with primers designed based on its 5 0 -UTR sequence; further analysis has led to the identification of novel RARb2 transcripts containing short 5 0 -UTRs that exhibited higher translation efficiency in breast cancer cells. These results indicate that the previously identified RARb2 transcript with long 5 0 -UTR could represent less functional form of RARb2.
In order to characterize the 5 0 region of RARb2 in MCF10 series of cell lines, we performed RT-PCR analysis with total mRNA isolated from these cell lines using two primer pairs specifically designed for different region of RARb2. As shown in Figure 1a , we detected the expression of RARb2 mRNA with primers RARb2-475F (number identifies the primer location relative to transcription start site (TSS) based on GeneBank RARb sequence NM_000965) and RARb2-730R. However, we did not detect RARb2 when the forward primer was replaced with RARb2-110F (this primer pair is supposed to amplify both RARb2 and RARb4). RT-PCR analysis with another primer pair (RARb2-79F and RARb2-401R) confirmed the results (data not shown), suggesting that MCF10 series of cell lines expressed RARb variants with different 5 0 -end. In order to distinguish between multiple 5 0 -ends, we performed 5 0 -RACE analysis of the MCF10A total RNA with two RARb2-specific primers, RARb2-1104RP and RARb2-727RP, respectively (Figure 1b ). Using these two primers, we failed to detect the expected RARb2 fragments with size B1.15 kb (Figure 1b, lane 1) and B0.78 kb (Figure 1b, lane 2) , respectively, but consistently detected two bands with smaller sizes (B0.45 kb shorter, Figure 1b, lanes 1 and 2) . We further 5 0 -RACEanalysed MDA-MB435 cells that expressed high level of RARb2 (Sommer et al., 1999) with primer RARb2-1104RP. We detected both expected RARb2 fragment with size of B1.15 kb (labeled as RARb2L in Figure 1b ) and a smaller fragment with size of B720 bp (labeled as RARb2S, B0.45 kb shorter).
The 5 0 -RACE product was cloned and sequenced. Novel RARb2 transcript variants with short 5 0 -UTRs were identified. Table 1 lists the 5 0 -RACE mapping of the transcriptional start sites (TSS) of these transcript variants. In order to confirm the accuracy and effectiveness of 5 0 -RACE mapping of TSS, we also analysed the RARb2 fragment of B1.15 kb (RARb2L from Figure 1b ) with the same method. Two TSS ( þ 1 and À11; þ 1 identifies the first nucleotide of the putative TSS based on GeneBank sequence data (NM_000965)) of the full-length RARb2 were identified in MDA-MB435 cells. At the present time, we have analysed two clones. It is possible that multiple TSS of RARb2 may be present and remains unidentified in this breast cancer cell line. Correspondingly, multiple TSS were identified for RARb2 transcript variants with short 5 0 -UTR from MDA-MB435 cells, whereas only two TSS ( þ 444 and þ 415) were identified for RARb2 variants from MCF10A cells, corresponding to the two bands identified by 5 0 -RACE analysis in this cell line ( Figure 1b , lanes 1 and 2). Interestingly, the DNA sequences flanking the two TSS of RARb2 variants from MCF10A cells are the same; both are TTTGC ( Figure 1c ). Same TSS for RARb2 variant was also identified from normal mammary epithelial cell (HMEC) ( Table 1) . As shown in Figure 1b , the lower 0 -RACE analysis of MCF10A and MDA-MB435 mRNA with SMART RACR cDNA amplification Kit (Clontech Laboratories, Inc., Palo Alto, CA, USA) according to the User Manual. For MCF10A cells, two primer pairs, UPM (universal primer mix, provided with kit)-RARb2-1104R (TCGGACTCGATGGTCAGCACTGGAA) (lane 1) and UPM-RARb2-727R (TGTCCTGGCAGACGAAGCAGG GTTT) (lane 2) were used for analysis, while for MDA-MB435, one primer pair UPM-RARb2-1104R (lane 1) was used for analysis. In MCF10A cells, the full-length RARb2 (expected size: 1156 bp for primers UPM-RARb2-1104R (lane 1); 779 bp for primers UPM-RARb2-727R (lane 2)) was not detectable, but two bands at B720 bp (for primer pair UPM-1104R, arrow) was consistently detectable for both primers pairs (lanes 1 and 2). In MDA-MB435 cells, both full-length RARb2 (size B1.15 kb) and a band at B720 bp were detectable. M, DNA marker. (c) 5 0 -UTR cDNA sequence of full-length RARb2 transcript. Nucleotides are numbered relative to the TSS of full-length RARb2 mRNA. The 5 0 -uORFs' start codons (uATG) were underlined. The sequences surrounding the alternative TSS for the transcript variants in MCF10A cells (see Table 1 ) were underlined and the TSS were indicated above the arrow. Translation of RARb2 begins at þ 469 of full-length RARb2 transcript, indicated above the right-angled arrow Note: The nucleotide position of hRARb2 mRNA is designated with +1 identifying the first nucleotide of the putative transcriptional start site based on GeneBank sequence data (X51650, NM_000965, M96016)
RARb2 transcript variants with short 5 0 -UTR X Peng et al brighter band below the RARb2S bands was recently identified by our group as a novel RARb isoform, RARb5 (Peng et al., 2004a) .
To detect quantitatively the expression of full-length RARb2 transcripts and total RARb2 transcripts, realtime RT-PCR was performed with RARb2-specific primers. Although MCF10A series of cell lines express short RARb2 transcripts only and are good model for the identification of these short transcripts, it appears that RARb2 transcripts were not significantly mediated by atRA (Figure 1a) . Therefore, we selected ER-positive T47D and ER-negative MDA-MB435 breast cancer cell lines to further address the regulation of both full-length and short transcripts. As shown in Figure 2 , both fulllength RARb2 transcript and total RARb2 transcripts were significantly upregulated by atRA in both ERpositive T47D and ER-negative MDA-MB435 cells. In T47D cells, atRA treatment increased the expression of full-length RARb2 transcript by 17-fold, whereas increased total (full-length plus short) RARb2 transcripts by 41-fold; on the other hand, in MDA-MB435 cells, atRA increased full-length RARb2 transcript by 14-fold and increased total RARb2 transcripts only by 8-fold (Figure 2a ). These results suggest that both fulllength and short RARb2 transcripts were upregulated by atRA in these cell lines; in T47D cells, short RARb2 transcripts were preferentially upregulated, whereas in MDA-MB435 cells, full-length RARb2 transcripts were preferentially upregulated. The ratio analysis of total RARb2 transcripts to full-length RARb2 transcripts (total/full length) confirmed this result ( Figure 2b , the change of ratio roughly reflects the change of short transcripts), since the ratio was greater than control in T47D cells and lower than control in MDA-MB435 cells after atRA treatment. The effect of atRA on cell proliferation was evaluated by MTT assay (Carmichael et al., 1987) in these two cell lines. As shown in Figure 2c , 7-day treatment with 1 mM atRA significantly inhibited cell proliferation by 40% in T47D cells, but failed to inhibit cell proliferation in MDA-MB435 cells. This cellular sensitivity to atRA is correlated to the upregulation of short RARb2 transcripts, suggesting that the expression of short RARb2 transcripts could contribute to cellular sensitivity.
To test whether short RARb2 transcripts are more functional, we further accessed the effects of long and short 5 0 -UTR on translation efficiency. Full-length (À3/ þ 468) and short ( þ 415/ þ 468) 5 0 -UTRs of RARb2 transcripts were cloned into the upstream of luciferase ORF of PGL3C vector (Figure 3a) . Transient transfection assay demonstrated that the presence of full-length 5 0 -UTR inhibited luciferase translation by 60% in both MCF-7 and T47D breast cancer cell lines (Figure 3b ), whereas the short 5 0 -UTR had no inhibitory effects in both cell lines as compared to the translation efficiency of the control vector PGL3C. To confirm these results, we also cloned the two 5 0 -UTRs to the upstream of RARb2 ORF in the pcDNA3.1(RARb2) expression vector and performed in vitro translation with these expression vectors containing different 5 0 -UTRs. Similar results were obtained (Figure 3c ). These results suggest Figure 2 RT-PCR analysis of full-length RARb2 transcript and total RARb2 transcripts in breast cancer cells in correlation to cellular response to atRA. T47D and MDA-MB435 cells were treated with atRA (1 mM) for 24 h, total RNA was then analysed by quantitative RT-PCR with 1 ml RT product using 7900HT Sequence Detection System (ABI, Applied Biosystem) and ABI 2 Â SYBR Green PCR Master Mix (ABI #4309155) according to ABI's recommended guidelines. (a) Real-time PCR analysis of the cDNA samples from the two cell lines showing relative changes of full-length RARb2 transcript and total RARb2 transcripts normalized to b-actin (their controls are set as 1) after atRA treatment. Results are expressed as the mean value of duplicate experiments. Primers for real-time PCR for total RARb2 transcripts were 584FP (GATTGACCCAAACCGAATGGCAGCA, Tm ¼ 66C) and 730RP; primers for full-length RARb2 were 295FP (GGCTTTTA GCTGGCTTGTCTG) and 420RP (GGAGGCAAATGGCATA GAAA). (b) Real-time PCR analysis showing the change of ratio of total RARb2 transcript (RARb2T) to full-length RARb2 (RARb2F), which roughly represents the change of short 5 0 -UTR RARb2 transcripts. (c) MTT assay of cell proliferation in response to atRA. Cells were treated for 7 days with 1 mM atRA. Data are expressed as the percentage of DMSO control7s.d. of eight wells. All data shown are representative of three independent experiments. ***Po0.001 compared to control. Note the correlation between cellular sensitivity and the ratio of total RARb2 transcript to full-length RARb2 in response to atRA RARb2 transcript variants with short 5 0 -UTR X Peng et al that full-length 5 0 -UTR greatly inhibited RARb2 translation, whereas short 5 0 -UTR had no significant effect on translation efficiency for in vitro translation.
Owing to the identification of these RARb2 transcript variants with short 5 0 -UTRs and RT-PCR analysis of the regulation of full-length and total RARb2 transcripts by atRA, we suspected that the 5 0 region flanking the short 5 0 -UTRs of RARb2 variants could play a role of promoter for the transcription of these variants with short 5 0 -UTRs. We therefore cloned this region (À3/ þ 468) to the upstream of luciferase ORF of promoterless PGL3 basic vector in both sense and antisense orientation. Transient transfection assay demonstrated that this region has no significant promoter activity in MCF-7 cells (Figure 4) , as the luciferase activity did not show any difference from that of empty vector PGL3B-transfected cells in either the presence or absence of atRA stimulation. Similar results were also obtained from T47D cells (data not shown). These results suggest that this region does not play a role as an independent promoter.
RARb gene was first identified in 1987 (de ; in this report, Northern blot analysis of RARb from different tissues and cells had revealed two RARb bands (B3 and 2.5 kb), the lower band was not detectable using probe specific to the 5 0 -UTR region of RARb, suggesting that the two RARb transcripts differ at least in their 5 0 -untranslated leader sequence. These results are consistent with our observations. Similar results have also been reported by others (Swisshelm et al., 1994) and demonstrate the presence of two RARb transcripts. However, the difference of the two transcripts has never been precisely characterized. Here, we provide the first evidence for the existence of multiple RARb2 transcript variants that only differ in their 5 0 -UTR and these variants are expressed in both normal and neoplastic breast epithelial cells. It should be indicated that the RARb2 transcript variants with short 5 0 -UTR are different from RARb4, which is a splice variant of full-length RARb2 and uses CUG as its translation start codon. Therefore, cell lines not expressing full-length RARb2 such as MCF10A series of cell lines do not express RARb4 (Figure 1a ), while these cell lines still express short RARb2 transcripts. The identification of these variants raises new questions: Does the 5 0 -UTR of different transcripts influence the translation efficiency? Whether the short transcripts are generated by alternative splicing or from different TSS. 0 -UTRs of RARb2 were cloned to the upstream of RARb2 ORF of pcDNA3.1(RARb2) expression vector. Then, in vitro translation was performed with different pcDNA3.1(RARb2) constructs containing full-length or short 5 0 -UTR of RARb2. In vitro translation products were subjected to Western blot analysis with RARb specific antibody (sc-552, Santa Cruz). M, protein marker; 1-4, in vitro translation product with 1. pcDNA3.1(RARb2) expression vector; 2. pcDNA3.1(RARb2) containing short 5 0 -UTR; 3. pcDNA3.1(RARb2) containing long 5 0 -UTR; 4. pcDNA3.1 empty vector Figure 4 Full-length 5 0 -UTR of RARb2 has no promoter activity in MCF-7 cells. PGL3 vectors containing full-length of RARb2 5 0 -UTR (À3/ þ 468) in sense (ÀS) and antisense (ÀAS) orientation as promoter was cotransfected with b-galactosidase construct into MCF-7 cells. After 5-h incubation with different constructs, cells were treated with atRA (1 mM) for 24 h, and then luciferase activity was assayed. Luciferase activity was normalized to b-gal. PGL3 control vector was used as positive control vector. There were no significant difference in luciferase activity among cells transfected with PGL3 basic vector and other PGL3-5 0 -UTR constructs. Results are expressed as the mean7s.e.m. of three independent experiments performed in triplicate RARb2 transcript variants with short 5 0 -UTR X Peng et al
The first question was addressed through transfection and in vitro translation assay. As expected, the short transcripts exhibited highest translation efficiency, whereas the translation efficiency of the full-length transcripts greatly decreased in both cells and in vitro translation assay. Upregulation of short transcripts are further correlated with cellular sensitivity, suggesting that the short transcripts could have greater functional significance.
To address the second question, we cloned the 5 0 -UTR region to promoterless PGL3 basic vector to test its promoter activity. We were unable to detect any promoter activity of this 5 0 -UTR region. We therefore thought the short transcripts could be formed by posttranscriptional modification (splicing or truncation), since the flanking sequence of the start sites of the two short transcripts from MCF10A cells are the same (TTTGC). However, the analysis of RARb2 transcripts from MDA-MB435 cells excluded this possibility. The MDA-MB435 cells have multiple start sites for both the short and long transcripts, suggesting that these short transcripts are possibly from different TSS rather than an enzyme modification, because enzyme generally cuts precisely at specific sequence site. Real-time PCR analysis apparently also supports this hypothesis, since the expression of both long and short RARb2 transcript appeared to be stimulated by atRA in a similar way. Although the 5 0 -UTR of full-length RARb2 has no promoter activity, it is still possible that this region together with P2 promoter that has been known to control the transcription of full-length RARb2 directs the transcription of short RARb2 transcripts. Our data on MCF10A cells support this hypothesis. In this cell line, P2 promoter controlling the full-length RARb2 transcripts are silenced, whereas the short transcripts are still expressed, revealing different regulation mechanisms of different transcripts in these cells. We previously detected low level of RARb2 protein in these cell lines and that the protein expression was also induced by retinoids (Peng et al., 2004b) ; therefore, it is possible that RARb2 transcript variants with short 5 0 -UTRs provide basal level of transcripts for RARb2 protein translation. In agreement with this hypothesis, Sommer et al. (1999) reported that MCF-7 and MDA-MB231 breast cancer cells did not express detectable (by Northern blot) RARb2 mRNA, but expressed detectable RARb2 protein, while MDA-MB435 cells expressed high level of full-length RARb2, but did not express high level of RARb2 protein. Further studies are needed to evaluate the function of the flanking sequence (TTTGC) of the TSS of the short RARb2 transcripts, which is also conserved in the 5 0 -UTR close to TSS of mouse RARa2 and mouse RARb2 (Zimmer et al., 1994) , as well as how the promoter regulate the expression of these RARb2 transcript variants. It is known that RARb2 promoter is silenced in some breast cancer cells through methylation (Sirchia et al., 2000) , but it is still unknown how the promoter methylation influence the expression of different transcripts of RARb2. We also conducted studies to assess whether deacetylase inhibitor such as trichostatin A (TSA) affects the RA-induced RARb2 expression in MCF10AT cells. Our data, however, did not show significant alterations of RARb2 expression in this cell line after TSA treatment, although TSA greatly inhibited cell proliferation (data not shown).
It should be noted that RARb2 transcripts with short 5 0 -UTRs could be expressed at low level and might not always be detectable by Northern blot in some cells such as MCF10A (Li et al., 1995) and MCF-7 cells (Sommer et al., 1999) , but detectable by RT-PCR. This may partially explain the mismatch between protein level and RNA level in some cells.
In summary, we have identified novel RARb2 transcripts with short 5 0 -UTR that are more functional for protein translation. It appears that their expression is also controlled by P2 promoter and stimulated by atRA. Their upregulation is correlated to cellular sensitivity to atRA. These results provide the basis for further studies on the regulation of these more functional RARb2 transcripts as a target for breast cancer chemoprevention and treatment with retinoids.
